The chemotherapeutic agents comprising mFOLFIRINOX—oxaliplatin, irinotecan, and 5-fluorouracil—have been shown to enhance NK-cell-mediated cytotoxicity by upregulating ligands such as NKG2D, DNAM-1, and NKp30 ligands across various tumor types, including pancreatic cancer [11,12,13,14,15,19]. This evidence concerns the gene CD226 and familial pancreatic carcinoma.